New Diffblue Testing Agent Automatically Generates Comprehensive Regression Test Suites To Derisk Application Modernization ...

ASCO updates stage IV driver-negative NSCLC guidance: put molecular testing first, add Teliso‑V, and navigate murky frontline choices. In this minisode of Treating Together, we break down the latest ...

I test a lot of coffee machines. Like, a lot of them. The Ratio Four is the small-batch brewer I use to try new kinds of coffee. Coffee is the original office biohack and the nation’s most popular ...

Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure. Overall survival (OS) in ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

LITTLE ROCK, Ark. (KATV) — It’s a question so many women have asked: "If my mother had breast cancer, will I get it too?" But doctors say knowledge is power, and that power could save your life. UAMS ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment guidelines. A retrospective analysis showed improved PFS for NOTCH1-mutated CLL ...

In 2023, Jill Martin took a test that changed her life. She underwent genetic testing for breast cancer and learned she had a BRCA2 mutation, which increases one’s risk of developing breast and other ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...